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began, genetic tests were available for about 100 diseases -most of them caused by just one faulty gene, such as the mutations that cause Tay-Sachs and cystic fi brosis. As genomic technologies matured and sequencing became less costly, companies began developing tests for a wider range of complex, multigenic, common diseases. These were initially offered by laboratories used by physicians, but more recently dozens of companies have begun marketing such tests on a DTC basis.
The fi rst advertising campaign for a genetic test, Myriad Genetics' BRACAnalysis, took place in the early 2000s. It included television ads for the test, which detects mutations in the BRCA1 and BRCA2 genes that raise the risk of breast and ovarian cancers. Myriad also advertised in the playbill of the Broadway play, Wit , which was about a professor dying of ovarian cancer. Audrey Chapman, Ph.D., professor of medical ethics and humanities at the University of Connecticut School of Medicine in Farmington, analyzed that campaign and concluded that it essentially marketed the BRCA1 and BRCA2 test to the general public, even though it is not an appropriate test for most of the population ( On the same day, the Government Accountability Offi ce issued a highly critical report of the tests, citing, among other problems, misleading test results, deceptive marketing, and other questionable practices.
Controversy has long simmered about whether, or how, to regulate genetic tests, in particular DTC tests ( see sidebar). But the events on July 22 brought the issue to a head. In the months that followed, articles in Nature , the New England Journal of Medicine , The Economist , and other publications debated DTC genetic testing. Critics pointed to all the issues raised in the hearing and report, and more broadly, the government's responsibility to protect consumers; supporters stressed an individual's right to unfettered access to genetic information. And with FDA regulation of some sort a virtual certainty, both sides began to focus on what aspects of the industry should be regulated and just how far the regulations should go.
Rapid Increase
It took nearly two decades for the debate, and the FDA, to reach this point. But now regulation is on the way. Just before the hearing on Capitol Hill, the FDA held a 2-day meeting for stakeholders, followed by a 60-day period for public comment to gather opinions on developing the best regulatory framework.
Dueling Opinions
Many of the opinions focus on what happens after the test is performed. In one of the Nature editorials, Arthur Beaudet, M.D., chair of the department of molecular and human genetics at Baylor College of Medicine in Houston, argues that the interpretation of tests should be left to board-certifi ed specialists. "My focus is that the FDA should not try to regulate assessment of clinical sensitivity, clinical specifi city, and clinical utility to any specifi c extent in their process," he said. He proposes that genetic testing be regulated in two parts, similar to imaging, where the FDA regulates the machines that do the imaging but board-certifi ed radiologists interpret the results. Board-certifi ed molecular geneticists, molecular pathologists, and "in the future, perhaps, board-certifi ed genomicists" should interpret genetic test results, he said.
Ellen Matloff, director of genetic counseling at the Yale Cancer Center in New Haven, Conn., agrees that interpreting test results takes a specialist. In a recent study, she showed that even genetic tests ordered and interpreted by physicians often result in incorrect diagnoses, recom mendations, and unnecessary procedures. Matloff ar gues that only certifi ed cancer geneticists should advise patients ( Connecticut Medicine , August 2010). "All genetic tests, whether sold over the Internet or ordered by a doctor, should receive the same FDA oversight as pharmaceuticals, with risks and benefi ts clearly stated outright, the way that commercials for Viagra do," she said.
In a second editorial in Nature , Gail Javitt, J.D. , research scholar at Johns Hopkins' Berman Institute of Bioethics, argues that focusing on how the genetic tests are marketed is a mistake. Nor should the FDA create a separate regulatory scheme solely for DTC tests, said Javitt, who also serves as counsel at the law fi rm Sidley Austin in Washington, D.C. Her position is that regulatory agencies need to create a broad framework to ensure the quality of all health-related tests.
"Just because a test is sold DTC doesn't mean it's a bad test, although the fact that it is being sold DTC is certainly a factor that should be considered in addressing its risk," she said. "A DTC test may test for a highrisk condition, such as BRCA1/2 status, or a low-risk condition, such as type of earwax, and should be regulated according to risk, not solely on how it is marketed. We need to think more broadly about where greater scrutiny is needed for higher-risk tests, not just about how they are sold." But cancer geneticist Kenneth Offi t, M.D. , at Memorial Sloan -Kettering Cancer Center in New York, does see particular danger in DTC marketing of genetic tests because of the uncertain quality of the tests and the absence of counseling. While often sold, until recently, as entertainment or for educational purposes to elude regulation, he said, "these genetic tests are, in fact, medical tests, and as such should be put in a medical context, which would require government regulation and genetic counseling for patients."
Offi t also strongly criticized the quality of the tests. "DTC tests and many other [laboratory tests] are based on genomewide association research studies [identifying SNPs] and offer incomplete, ambiguous, or clinically meaningless information," he said. "Many of these tests are for very common, low-penetrance genetic variations, which are associated with low or very modest increase in risks." 
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The FDA is now considering requiring counseling for DTC tests for high-risk mutations, "which have the potential to cause distress," Gutierrez said. Such distress, well known to clinical geneticists, results from ambiguous test results.
"We see the same negative effects in women tested for the BRCA genes who were given ambiguous results as those seen in patients in the early 1990s who received ambiguous test results for Huntington disease," Offi t said. "Women with such results, such as missense mutations or 'variants of unknown signifi cance, ' often experienced more upset than those testing either positive or negative for a known mutation."
Access to Genetic Information
Not surprisingly, companies like Pathway Genomics support patients' unfettered access to genetic information. Even those who want regulation acknowledge that access to health information is not an issue to be dismissed lightly. The law favors allowing consumers access to information relevant to their health, and the trend is toward not suppressing their access to such information, said Javitt, the lawyer from Johns Hopkins. A complete ban of the tests would be diffi cult for the FDA to justify, she wrote.
The industry argues that the tests offer educational value for patients even when the results may not be clinically useful. "We do not believe that every report need have a direct clinical action associated with it -there can be a substantial personal 
